Cargando…

Should we abandon hormonal therapy in endometrial cancer? Outcomes of recurrent and metastatic endometrial cancer treated with systemic progestins

PURPOSE: The objective of this study is to determine primary survival endpoints in women with recurrent and metastatic endometrial carcinoma (RMEC) treated with progestins. METHODS: A retrospective chart review was conducted at The Ottawa Hospital using electronic medical records. Inclusion criteria...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kulkarni, A., Wright, N. M. Andrews, Forget, A. N., Ramsay, T., Mallick, R., Weberpals, J. I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469659/ https://www.ncbi.nlm.nih.gov/pubmed/37417528 http://dx.doi.org/10.1002/cam4.6276

Ejemplares similares

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
por: Lv, Mu, et al.
Publicado: (2022)

Recurrent Endometrial Stromal Sarcoma: Treatment with a Progestin and Gonadotropin Releasing Hormone Agonist
por: duPont, Nefertiti Chianti, et al.
Publicado: (2010)

Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis
por: Shao, Fengping, et al.
Publicado: (2023)

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management
por: Nwanodi, Oroma
Publicado: (2017)

Identification of Genes and Pathways Differentially Expressed in Progestin Responsive Endometrial Cancer and Hyperplasia
por: Gertz, Jay, et al.
Publicado: (2021)

Chlorpromazine Sensitizes Progestin-Resistant Endometrial Cancer Cells to MPA by Upregulating PRB
por: Cui, Yunxia, et al.
Publicado: (2021)

The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta‐analysis
por: van Weelden, Willem Jan, et al.
Publicado: (2022)

Thyroid Hormone Receptor β Knockdown Reduces Suppression of Progestins by Activating the mTOR Pathway in Endometrial Cancer Cells
por: Ren, Bingtao, et al.
Publicado: (2022)

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019)

NrCAM secreted by endometrial stromal cells enhances the progestin sensitivity of endometrial cancer cells through epigenetic modulation of PRB
por: Cheng, Yali, et al.
Publicado: (2022)

Identification and Validation of MSX1 as a Key Candidate for Progestin Resistance in Endometrial Cancer
por: Yang, Linlin, et al.
Publicado: (2020)

Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma
por: Newtson, A.M., et al.
Publicado: (2017)

Should Endometrial Cancer Treatment Be Centralized?
por: Mandato, Vincenzo Dario, et al.
Publicado: (2022)

Testing Women With Endometrial Cancer for Lynch Syndrome: Should We Test All?
por: Ma, Jun, et al.
Publicado: (2013)

Endometrial Cancer Stem Cells: Where Do We Stand and Where Should We Go?
por: Banz-Jansen, Constanze, et al.
Publicado: (2022)

Hormonal Biology of Endometrial Cancer
por: Skinner, L. G.
Publicado: (1979)

Progestins Related to Progesterone and Testosterone Elicit Divergent Human Endometrial Transcriptomes and Biofunctions
por: Houshdaran, Sahar, et al.
Publicado: (2020)

Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer
por: Falcone, Francesca, et al.
Publicado: (2017)

Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1
por: Yang, Yuan, et al.
Publicado: (2017)

Study of the Characterization of Side Population Cells in Endometrial Cancer Cell Lines: Chemoresistance, Progestin Resistance, and Radioresistance
por: Liu, Bing-jie, et al.
Publicado: (2020)

Prognostic factors of oncologic outcomes after fertility-preservative management with progestin in early-stage of endometrial cancer
por: Roh, Hyun Jin, et al.
Publicado: (2021)

Aspiration in injections: should we continue or abandon the practice?
por: Sepah, Yasir, et al.
Publicado: (2017)

Why we should abandon the misused descriptor ‘erythema’
por: Finlay, A.Y., et al.
Publicado: (2021)

Identification of potential models for predicting progestin insensitivity in patients with endometrial atypical hyperplasia and endometrioid endometrial cancer based on ATAC-Seq and RNA-Seq integrated analysis
por: Hu, Jia-Li, et al.
Publicado: (2022)

Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin
por: Pant, Alok, et al.
Publicado: (2012)

Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?
por: Baek, Ji Sun, et al.
Publicado: (2016)

Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway
por: Wang, Yiying, et al.
Publicado: (2016)

RNA‐seq and ATAC‐seq analysis of CD163 (+) macrophage‐induced progestin‐insensitive endometrial cancer cells
por: Wang, Lulu, et al.
Publicado: (2022)

Partial ablation of endometrial glands in dogs after exposure to progestin during the neonatal period
por: Teixeira, Natália Soares, et al.
Publicado: (2018)

New therapies for advanced, recurrent, and metastatic endometrial cancers
por: Makker, Vicky, et al.
Publicado: (2017)

Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system
por: Kim, Da Hee, et al.
Publicado: (2017)

Should we abandon manual muscle strength testing in the ICU?
por: Hermans, Greet, et al.
Publicado: (2011)

We should not abandon therapeutic cooling after cardiac arrest
por: Polderman, Kees H, et al.
Publicado: (2014)

‘Acute Heart Failure’: Should We Abandon the Term Altogether?
por: Straw, Sam, et al.
Publicado: (2022)

Preclinical Model in Sepsis: Should We Abandon the CLP? [Letter]
por: Joffre, Jeremie
Publicado: (2023)

Molecular profiling identifies synchronous endometrial and ovarian cancers as metastatic endometrial cancer with favorable clinical outcome
por: Reijnen, Casper, et al.
Publicado: (2020)

Endometrial cancer
por: Sobel, Mara, et al.
Publicado: (2021)

PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy
por: Liu, Hua, et al.
Publicado: (2017)

Potential alternative progestin therapy for low-grade endometrial stromal sarcoma: A case report
por: Maenohara, Shoji, et al.
Publicado: (2020)

Past, present, and future of hormonal therapy in recurrent endometrial cancer
por: Carlson, Matthew J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lqgpt391fn39nrfosha4scogvo